| 000 | 01831 a2200577 4500 | ||
|---|---|---|---|
| 005 | 20250518003604.0 | ||
| 264 | 0 | _c20190924 | |
| 008 | 201909s 0 0 eng d | ||
| 022 | _a2375-2548 | ||
| 024 | 7 |
_a10.1126/sciadv.aat3386 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aÄmmälä, C | |
| 245 | 0 | 0 |
_aTargeted delivery of antisense oligonucleotides to pancreatic β-cells. _h[electronic resource] |
| 260 |
_bScience advances _c10 2018 |
||
| 300 |
_aeaat3386 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aDrug Delivery Systems _xmethods |
| 650 | 0 | 4 |
_aForkhead Box Protein O1 _xgenetics |
| 650 | 0 | 4 | _aGene Silencing |
| 650 | 0 | 4 |
_aGlucagon-Like Peptide-1 Receptor _xgenetics |
| 650 | 0 | 4 | _aHEK293 Cells |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInsulin-Secreting Cells _xdrug effects |
| 650 | 0 | 4 | _aMice, Inbred C57BL |
| 650 | 0 | 4 | _aMice, Knockout |
| 650 | 0 | 4 |
_aOligonucleotides, Antisense _xadministration & dosage |
| 650 | 0 | 4 |
_aRNA, Long Noncoding _xgenetics |
| 650 | 0 | 4 | _aGlucagon-Like Peptide-1 Receptor Agonists |
| 700 | 1 | _aDrury, W J | |
| 700 | 1 | _aKnerr, L | |
| 700 | 1 | _aAhlstedt, I | |
| 700 | 1 | _aStillemark-Billton, P | |
| 700 | 1 | _aWennberg-Huldt, C | |
| 700 | 1 | _aAndersson, E-M | |
| 700 | 1 | _aValeur, E | |
| 700 | 1 | _aJansson-Löfmark, R | |
| 700 | 1 | _aJanzén, D | |
| 700 | 1 | _aSundström, L | |
| 700 | 1 | _aMeuller, J | |
| 700 | 1 | _aClaesson, J | |
| 700 | 1 | _aAndersson, P | |
| 700 | 1 | _aJohansson, C | |
| 700 | 1 | _aLee, R G | |
| 700 | 1 | _aPrakash, T P | |
| 700 | 1 | _aSeth, P P | |
| 700 | 1 | _aMonia, B P | |
| 700 | 1 | _aAndersson, S | |
| 773 | 0 |
_tScience advances _gvol. 4 _gno. 10 _gp. eaat3386 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1126/sciadv.aat3386 _zAvailable from publisher's website |
| 999 |
_c28962910 _d28962910 |
||